Recent News

• 11.26.2025 - IO Biotech Announces Participation in Upcoming December Investor Conferences
• 11.14.2025 - IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
• 10.20.2025 - IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
• 09.29.2025 - IO Biotech Provides Update Following Pre-BLA Meeting with FDA
• 09.23.2025 - IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
• 09.04.2025 - IO Biotech Announces Participation in Upcoming Investor Conferences
• 08.14.2025 - IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Recent Filings

• 11.21.2025 - 8-K Current report
• 11.18.2025 - 8-K Current report
• 11.18.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - 8-K Current report
• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.29.2025 - 8-K Current report
• 09.29.2025 - EX-99.1 EX-99.1